<p>德意志银行在最近向证券交易委员会提交的 13F 表格中表示，在第一季度将其在百时美施贵宝公司（NYSE:BMY - 免费报告）的股份增持了 0.1%。该基金在此期间购买了 13,995 股后，持有该生物制药公司 9,580,456 股股票。截至最近的 SEC 文件，德意志银行持有的百时美施贵宝股份约占 0.47%，价值 584,312,000 美元。</p>
<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p>其他一些对冲基金和机构投资者也调整了对 BMY 的持股。Pinney &amp; Scofield Inc.在第四季度购买了价值约 25,000 美元的百时美施贵宝新股份。Park Square Financial Group LLC 在第四季度购买了价值约 26,000 美元的百时美施贵宝新股份。Global Wealth Strategies &amp; Associates 在第一季度将其在百时美施贵宝的持股增加了 137.5%。Global Wealth Strategies &amp; Associates 现在拥有 475 股该生物制药公司的股票，价值 29,000 美元，此前在此期间又购买了 275 股。Transce3nd LLC 在第四季度购买了价值约 28,000 美元的百时美施贵宝新股份。最后，Harel Insurance Investments &amp; Financial Services Ltd.在第一季度获得了价值 31,000 美元的百时美施贵宝新股份。机构投资者和对冲基金持有该公司 76.41% 的股份。</p>
<p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
<h2>百时美施贵宝价格表现</h2>
<p>周四，NYSE BMY 的开盘价为 44.82 美元。该股票的 50 日简单移动平均线为 47.41 美元，200 日简单移动平均线为 52.06 美元。百时美施贵宝公司的 12 个月最低价为 42.96 美元，最高价为 63.33 美元。该股票的市值为 912.4 亿美元，市盈率为 18.07，市盈增长比率为 2.35，贝塔系数为 0.36。该公司的债务与股本比率为 2.54，速动比率为 1.11，流动比率为 1.21。</p>
<ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近在 7 月 31 日发布了季度财报。这家生物制药公司报告的季度每股收益为 1.46 美元，超出分析师一致预期的 1.07 美元，超过 0.39 美元。百时美施贵宝的股本回报率为 80.04%，净利润率为 10.58%。该公司在本季度的收入为 122.7 亿美元，而分析师预期为 113.2 亿美元。在去年同期，该公司每股收益为 2.07 美元。该公司的季度收入较去年同期增长了 0.6%。研究分析师预计百时美施贵宝公司今年将发布 6.74 美元的每股收益。</p>
<h2>百时美施贵宝宣布分红</h2>
<p>该公司最近还宣布了季度分红，已于 8 月 1 日（星期五）支付。7 月 3 日（星期四）登记在册的股东获得了 0.62 美元的分红。这代表着每年 2.48 美元的分红和 5.5% 的收益率。除息日期为 7 月 3 日（星期四）。百时美施贵宝的分红支付比率（DPR）目前为 100.00%。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>百时美施贵宝的疲软指引可能创造了机会</li>
</ul>
<p>BMY 已成为多份研究分析师报告的主题。Jefferies Financial Group 在 4 月 23 日的报告中将百时美施贵宝的目标价从 70.00 美元下调至 68.00 美元，并对该股票给予 “买入” 评级。Piper Sandler 在 4 月 22 日的研究报告中启动了对百时美施贵宝的覆盖，给予 “增持” 评级，目标价为 65.00 美元。Argus 在 4 月 25 日的研究报告中将百时美施贵宝的股票评级上调至 “持有”。Wall Street Zen 在 6 月 6 日的研究报告中将百时美施贵宝的股票评级从 “强烈买入” 下调至 “买入”。最后，Cantor Fitzgerald 在 4 月 22 日的研究报告中重申了 “中性” 评级，并将百时美施贵宝的目标价设定为 55.00 美元。一位分析师对该股票给予了卖出评级，十五位给予了持有评级，五位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，百时美施贵宝的平均评级为 “持有”，平均目标价为 56.38 美元。</p>
<p><strong>查看我们对 BMY 的最新分析</strong></p>
<h2>百时美施贵宝简介</h2>
<p>（免费报告）</p>
<p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供用于血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。该公司的产品包括 Eliquis，用于降低非瓣膜性房颤中中风/全身栓塞的风险，以及用于治疗深静脉血栓/肺栓塞；Opdivo 用于各种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>RSI 股票在第二季度暴涨 22%——PENN 能否匹配这种势头？</li>
<li>理解看涨期权交易量对成功期权交易的重要性</li>
<li>DigitalOcean 的专注如何推动爆炸性增长</li>
<li>如何投资蓝筹股</li>
<li>Celsius 股票能否继续保持其势头？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
<p>在考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

百时美施贵宝

<p>德意志银行（Deutsche Bank AG）在第一季度将其在百时美施贵宝（Bristol Myers Squibb Company，NYSE:BMY）的持股比例增加了 0.1%，目前持有 9,580,456 股，价值约为 5.8431 亿美元。其他机构投资者也调整了他们的持股。百时美施贵宝报告的季度每股收益（EPS）为 1.46 美元，超出预期，收入为 122.7 亿美元。该公司宣布季度股息为 0.62 美元，收益率为 5.5%。分析师对该股票的评级不一，平均目标价为 56.38 美元，普遍评级为 “持有”</p>

<p>Deutsche Bank AG grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 9,580,456 shares of the biopharmaceutical company's stock after purchasing an additional 13,995 shares during the period. Deutsche Bank AG owned about 0.47% of Bristol Myers Squibb worth $584,312,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>德意志银行在最近向证券交易委员会提交的 13F 表格中表示，在第一季度将其在百时美施贵宝公司（NYSE:BMY - 免费报告）的股份增持了 0.1%。该基金在此期间购买了 13,995 股后，持有该生物制药公司 9,580,456 股股票。截至最近的 SEC 文件，德意志银行持有的百时美施贵宝股份约占 0.47%，价值 584,312,000 美元。</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Pinney &amp; Scofield Inc. purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at about $25,000. Park Square Financial Group LLC purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $26,000. Global Wealth Strategies &amp; Associates boosted its stake in Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies &amp; Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 275 shares during the period. Transce3nd LLC purchased a new position in Bristol Myers Squibb during the 4th quarter worth approximately $28,000. Finally, Harel Insurance Investments &amp; Financial Services Ltd. acquired a new stake in Bristol Myers Squibb during the 1st quarter valued at $31,000. Institutional investors and hedge funds own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也调整了对 BMY 的持股。Pinney &amp; Scofield Inc.在第四季度购买了价值约 25,000 美元的百时美施贵宝新股份。Park Square Financial Group LLC 在第四季度购买了价值约 26,000 美元的百时美施贵宝新股份。Global Wealth Strategies &amp; Associates 在第一季度将其在百时美施贵宝的持股增加了 137.5%。Global Wealth Strategies &amp; Associates 现在拥有 475 股该生物制药公司的股票，价值 29,000 美元，此前在此期间又购买了 275 股。Transce3nd LLC 在第四季度购买了价值约 28,000 美元的百时美施贵宝新股份。最后，Harel Insurance Investments &amp; Financial Services Ltd.在第一季度获得了价值 31,000 美元的百时美施贵宝新股份。机构投资者和对冲基金持有该公司 76.41% 的股份。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
</div><h2>Bristol Myers Squibb Price Performance</h2>
<div class="lb-trans"><h2>百时美施贵宝价格表现</h2>
</div><p>NYSE BMY opened at $44.82 on Thursday. The stock has a 50-day simple moving average of $47.41 and a 200 day simple moving average of $52.06. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The stock has a market capitalization of $91.24 billion, a PE ratio of 18.07, a P/E/G ratio of 2.35 and a beta of 0.36. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.</p>
<div class="lb-trans"><p>周四，NYSE BMY 的开盘价为 44.82 美元。该股票的 50 日简单移动平均线为 47.41 美元，200 日简单移动平均线为 52.06 美元。百时美施贵宝公司的 12 个月最低价为 42.96 美元，最高价为 63.33 美元。该股票的市值为 912.4 亿美元，市盈率为 18.07，市盈增长比率为 2.35，贝塔系数为 0.36。该公司的债务与股本比率为 2.54，速动比率为 1.11，流动比率为 1.21。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The company had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same period in the previous year, the company earned $2.07 earnings per share. The company's quarterly revenue was up .6% compared to the same quarter last year. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近在 7 月 31 日发布了季度财报。这家生物制药公司报告的季度每股收益为 1.46 美元，超出分析师一致预期的 1.07 美元，超过 0.39 美元。百时美施贵宝的股本回报率为 80.04%，净利润率为 10.58%。该公司在本季度的收入为 122.7 亿美元，而分析师预期为 113.2 亿美元。在去年同期，该公司每股收益为 2.07 美元。该公司的季度收入较去年同期增长了 0.6%。研究分析师预计百时美施贵宝公司今年将发布 6.74 美元的每股收益。</p>
</div><h2>Bristol Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百时美施贵宝宣布分红</h2>
</div><p>The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.5%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，已于 8 月 1 日（星期五）支付。7 月 3 日（星期四）登记在册的股东获得了 0.62 美元的分红。这代表着每年 2.48 美元的分红和 5.5% 的收益率。除息日期为 7 月 3 日（星期四）。百时美施贵宝的分红支付比率（DPR）目前为 100.00%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>百时美施贵宝的疲软指引可能创造了机会</li>
</ul>
</div><p>BMY has been the topic of a number of research analyst reports. Jefferies Financial Group lowered their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, April 23rd. Piper Sandler initiated coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an &#34;overweight&#34; rating and a $65.00 target price on the stock. Argus raised shares of Bristol Myers Squibb to a &#34;hold&#34; rating in a research report on Friday, April 25th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, June 6th. Finally, Cantor Fitzgerald reissued a &#34;neutral&#34; rating and set a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of &#34;Hold&#34; and an average price target of $56.38.</p>
<div class="lb-trans"><p>BMY 已成为多份研究分析师报告的主题。Jefferies Financial Group 在 4 月 23 日的报告中将百时美施贵宝的目标价从 70.00 美元下调至 68.00 美元，并对该股票给予 “买入” 评级。Piper Sandler 在 4 月 22 日的研究报告中启动了对百时美施贵宝的覆盖，给予 “增持” 评级，目标价为 65.00 美元。Argus 在 4 月 25 日的研究报告中将百时美施贵宝的股票评级上调至 “持有”。Wall Street Zen 在 6 月 6 日的研究报告中将百时美施贵宝的股票评级从 “强烈买入” 下调至 “买入”。最后，Cantor Fitzgerald 在 4 月 22 日的研究报告中重申了 “中性” 评级，并将百时美施贵宝的目标价设定为 55.00 美元。一位分析师对该股票给予了卖出评级，十五位给予了持有评级，五位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，百时美施贵宝的平均评级为 “持有”，平均目标价为 56.38 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on BMY</strong></p>
<div class="lb-trans"><p><strong>查看我们对 BMY 的最新分析</strong></p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百时美施贵宝简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供用于血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。该公司的产品包括 Eliquis，用于降低非瓣膜性房颤中中风/全身栓塞的风险，以及用于治疗深静脉血栓/肺栓塞；Opdivo 用于各种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?</li>
<li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li>
<li>How DigitalOcean's Focus Is Fueling Explosive Growth</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Can Celsius Stock Keep Its Momentum Going Any Longer?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>RSI 股票在第二季度暴涨 22%——PENN 能否匹配这种势头？</li>
<li>理解看涨期权交易量对成功期权交易的重要性</li>
<li>DigitalOcean 的专注如何推动爆炸性增长</li>
<li>如何投资蓝筹股</li>
<li>Celsius 股票能否继续保持其势头？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

德意志银行股份公司持有百时美施贵宝公司（NYSE:BMY）价值 5.8431 亿美元的股票